Your email has been successfully added to our mailing list.

×
0.317784256559767 0.317784256559767 0.317784256559767 0.317784256559767 0.451895043731779 0.317784256559767 0.373177842565598 0.422740524781341
Stock impact report

MyoKardia Reports Positive Topline Results in Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

MYOKARDIA (MYOK) 
Last myokardia earnings: 2/27 04:05 pm Check Earnings Report
Company Research Source: GlobeNewswire
Phase 2 Study Met Primary and Key Secondary Endpoints Results from First Patient Cohort of PIONEER-HCM Accepted for Oral Presentation at Heart Failure Society of America’s 21st Annual Scientific Meeting Enrollment Complete in Second, Low-Dose Patient Cohort; Topline Data Expected Q1 2018 Company to Discuss Results on Conference Call Today at 8:30 a.m. EDT (5:30 a.m. PDT) SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) --  MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the “Company”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced positive topline data from the first patient cohort of its Phase 2 PIONEER-HCM study of mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy (oHCM) patients. This cohort met the primary endpoint of change in post-exercise peak left ventricular outflow tract (LVOT) gradient from baseline to week 12 as well as key seconda Show less Read more
Impact Snapshot
Event Time:
MYOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for MYOK alerts
Opt-in for
MYOK alerts

from News Quantified
Opt-in for
MYOK alerts

from News Quantified